Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enbrel etanercept: Phase IV data

In a post-hoc analysis of 566 patients in the double-blind Phase IV ASCEND trial, patients who received 50 mg once-weekly

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE